Dose reduction and discontinuation of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity

16 Dec

Helen Ramsay, Renea V Johnston, Sheila Cyril, Vanessa Glennon, Liesl Grobler, Deanne M Burgess, Bayden J McKenzie, Samuel L Whittle & Rachelle Buchbinder

Dose reduction and discontinuation of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity. Cochrane Database of Systematic Reviews 2024, Issue 12. Art. No.: CD015880. DOI: 10.1002/14651858.CD015880. Accessed 04 February 2025.

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015880/full

treatmentPainMusculoskeletalGuidelinesdeprescribingArthritisProtocol

Lucia Marcello

Dose reduction and discontinuation of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs (DMARDs) for people with psoriatic arthritis in remission or low disease activity

Variation in initial biopsy technique for primary melanoma diagnosis: A population-based cohort study in New South Wales, Australia

The potential for reducing greenhouse gas emissions through disease prevention: a secondary analysis of data from the CREDENCE trial